Valuation: Genovis AB

Market Cap 148.41Cr 15Cr 13Cr 12Cr 11Cr 21Cr 1.43TCr 21Cr 59Cr 745.76Cr 56Cr 55Cr 2.37TCr P/E 2026 *
74.5x
P/E 2027 * 43.2x
Enterprise Value 137.71Cr 14Cr 12Cr 12Cr 10Cr 19Cr 1.32TCr 20Cr 55Cr 692Cr 52Cr 51Cr 2.2TCr EV / Sales 2026 *
9.33x
EV / Sales 2027 * 7.18x
Free-Float
92.6%
Yield 2026 *
-
Yield 2027 * -
1 day+1.85%
1 week+6.54%
Current month+17.15%
1 month+20.22%
3 months+8.64%
6 months+13.64%
Current year+3.53%
1 week 20.05
Extreme 20.05
22.45
1 month 17.96
Extreme 17.96
22.45
Current year 15.64
Extreme 15.64
23.65
1 year 15.64
Extreme 15.64
23.65
3 years 15.64
Extreme 15.64
53.9
5 years 15.64
Extreme 15.64
90
10 years 2.18
Extreme 2.18
90
Manager TitleAgeSince
Chief Executive Officer 55 05/05/2015
Director of Finance/CFO 42 01/08/2026
Chief Tech/Sci/R&D Officer 42 01/01/2017
Director TitleAgeSince
Director/Board Member 77 01/01/2014
Director/Board Member 65 01/01/2019
Chairman 74 05/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
02/10/26 Buy 6,648 0.0101%
01/10/26 Buy

Chairman

45,000 0.0681%
30/09/26 Buy

Chief Executive Officer

28,000 0.0424%
Change 5-day change 1-year change 3-year change Capi.($)
+1.85%+6.54%-3.93%-47.24% 15Cr
-0.45%+2.12%-18.93%+10.37% 18TCr
+0.86%+2.15%-19.13%+15.77% 12TCr
+0.88%+1.88%+1.66%+35.46% 12TCr
-2.26%+18.07%-43.85%+5.76% 9.31TCr
-0.31%-4.72%-3.36%+74.94% 6.21TCr
+0.17%+1.64%+8.50%+82.24% 5.59TCr
+0.07%+0.42%+5.94%-22.27% 5.31TCr
+0.30%+1.70%-11.26%+42.01% 4.42TCr
+0.10%+3.37%-4.73%-8.71% 3.36TCr
Average +0.28%+2.71%-8.91%+18.83% 7.51TCr
Weighted average by Cap. +0.21%+2.37%-12.72%+23.84%

Financials

2026 *2027 *
Net sales 15Cr 1.49Cr 1.34Cr 1.23Cr 1.12Cr 2.09Cr 141.74Cr 2.11Cr 5.88Cr 74Cr 5.58Cr 5.47Cr 235.46Cr 19Cr 1.89Cr 1.69Cr 1.56Cr 1.42Cr 2.65Cr 179.67Cr 2.68Cr 7.45Cr 94Cr 7.08Cr 6.93Cr 298.48Cr
Net income 1.2Cr 12.1L 10.86L 10.04L 9L 16.98L 12Cr 17.19L 47.8L 6.03Cr 45.4L 44.45L 19Cr 3.37Cr 33.98L 30.49L 28.19L 25.53L 47.69L 32Cr 48.27L 1.34Cr 17Cr 1.28Cr 1.25Cr 54Cr
Net Debt -11Cr -1.08Cr -96.8L -89.49L -81.05L -1.51Cr -102.75Cr -1.53Cr -4.26Cr -54Cr -4.05Cr -3.96Cr -170.69Cr -14Cr -1.41Cr -1.27Cr -1.17Cr -1.06Cr -1.98Cr -134.44Cr -2.01Cr -5.58Cr -70Cr -5.3Cr -5.19Cr -223.34Cr
Projected Income Statement - Annual - Genovis AB
Logo Genovis AB
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Employees
42
Date Price Change Volume
28/26/28 SEK 22.00 +1.85% 2,01,474
27/26/27 SEK 21.60 +3.10% 1,07,820
26/26/26 SEK 20.95 -0.48% 1,54,205
23/26/23 SEK 21.05 +3.19% 2,24,332
22/26/22 SEK 20.40 -1.21% 1,68,843
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Genovis AB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
21.60SEK
Average target price
33.00SEK
Spread / Average Target
+52.78%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Genovis AB
  1. Stock Market
  2. Stocks
  3. GENO Stock